

**Remarks**

Applicant hereby elects under 35 U.S.C. §121 for further prosecution on the merits the claims of Group A, namely claims 42 – 45 and 104 – 108, without traverse. Applicant reserves the right to file one or more divisional applications at a later date capturing the subject matter set forth in any unelected claims.

Applicant also elects 35 U.S.C. §121 the species directed to piperazine derivatives, namely claims 43 – 45, 107 and 108 for further prosecution on the merits. Applicant understands that upon allowance of a generic claim (i.e., claim 104), Applicant will be entitled to consideration of any claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim, as provided by 37 CFR 1.141, such as, e.g., claims 105 and 106, as well as any newly added claims that incorporate any of the generic features of claim 104.

The extendable due date for response to the instant Office Action, under a one-month shortened statutory period, is **May 10, 2009**. Applicant hereby petitions for a one-month extension of time under 37 C.F.R. § 1.136(a), thereby extending the due date for response to June 10, 2009. In association therewith, Applicants hereby authorize the Commissioner to charge **Deposit Account No. 50-3994** in the amount of \$130.00, the fee set forth under 37 C.F.R. § 1.17(a)(2). Applicants do not believe that any additional fees are due in connection with this Response. However, in the unlikely event that any such fees are due, the Commissioner is hereby authorized to charge the same to Deposit Account No. 50-3994, from which the undersigned is authorized to draw funds.

Respectfully submitted,

/Jonathan P. Aumais/

Jonathan P. Aumais, Ph.D.  
Limited Recognition No. L0431  
Agent for Applicant  
(760) 476-6271

**Applied Biosystems, LLC**  
Intellectual Property Department  
5781 Van Allen Way  
Carlsbad, CA 92008

Date: June 10, 2009